Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908413 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Curis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01908413 is a Phase 1 study that was terminated before completion, run by Curis. The registered enrollment target is 23 participants.
The verdict
NCT01908413, a Phase 1 study, was terminated before completion, sponsored by Curis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma. CUDC-427 is a drug that is designed to antagonize proteins that prevent or interfere with cell death. The study is designed to assess the safety, including the maximum tolerated dose, the pharmacokinetics, and the anti-cancer activity of CUDC-427.
Interventions
- DRUG CUDC-427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908413
The ClinicalTrials.gov registry entry for NCT01908413 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CUDC-427 is the first listed.
NCT01908413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908413 about?
NCT01908413 is a clinical study titled "Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma". This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma. CUDC-427 is a drug that is designed to antagonize proteins that prevent or interfere with cell death. The study is designed to assess the safety, including the maximum t...
What is the current status of trial NCT01908413?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01908413?
The interventions under investigation include: CUDC-427 (DRUG).
Who is sponsoring clinical trial NCT01908413?
This trial is sponsored by Curis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.